Vancouver, BC — Tekmira Pharmaceuticals Corporation (TSX: TKM, Nasdaq: TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today that the Company’s President and Chief Executive Officer, Dr. Mark J. Murray, will present at the Piper Jaffray 22nd Annual Health Care Conference on Tuesday November 30, 2010 at 4:30 pm ET at the New York Palace Hotel in New York City. A webcast of the presentation will be available and can be accessed on the Company’s website, www.tekmirapharm.com.

About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners.  Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com.  Tekmira is based in Vancouver, B.C.
Contact Information  

Investors
Adam Peeler The Equicom Group
Phone: 416-815-0700 x 225
Email: apeeler@equicomgroup.com

Ian Mortimer
Executive Vice President and Chief Financial Officer
Phone: 604-419-3200  

Media
David Ryan
Longview Communications Inc. 
Phone: 604-694-6031
Email: dryan@longviewcomms.ca